Santa Barbara, CANCT07614776Now EnrollingIRB Ready

Neovascular Age-related Macular Degeneration Clinical Trial in Santa Barbara, CA

Access cutting-edge neovascular age-related macular degeneration treatment through this clinical trial at a research site in Santa Barbara. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this Santa Barbara location

Preparing your pre-screening questions…

Expert Care in Santa Barbara

Access neovascular age-related macular degeneration specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neovascular age-related macular degeneration treatment provided free

Apply for This Santa Barbara Location

Check if you qualify for this neovascular age-related macular degeneration clinical trial in Santa Barbara, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Santa Barbara

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Santa Barbara site if eligible
  4. 4Begin participation

About This Neovascular Age-related Macular Degeneration Study in Santa Barbara

The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

Men or women ≥ 50 years old, capable of giving signed informed consent
Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)
Total area of CNV (including both classic and occult components) \> 50% of the total lesion area in the SE
The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE
Presence of intra and/or subretinal fluid affecting the central subfield of the SE as identified by SD-OCT attributable to active CNV. The central subfield is defined as a circle with a diameter of 1 mm, centered on the fovea

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply at either screening or baseline, unless otherwise indicated per protocol:
Total lesion size \> 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye
Scar, fibrosis, or atrophy involving the central subfield in the study eye
Scar or fibrosis involving \> 50% of the total lesion in the study eye
Presence of retinal pigment epithelium tears or rips involving the macula in the study eye
History of any vitreous hemorrhage ≤ 4 weeks (28 days) before randomization in the study
Presence of other causes of CNV, including pathologic myopia (spherical equivalent ≥ 8 diopters negative or axial length ≥ 25 mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study
Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with anti-glaucoma medication) in the study eye
History or clinical evidence of DR, DME, idiopathic autoimmune uveitis, or any other vascular disease affecting the retina, other than nAMD in either eye
Evidence of active extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening or randomization
Uncontrolled blood pressure (defined as systolic \>160 mmHg or diastolic \>95 mmHg). Blood pressure needs to be stable for at least 12 weeks (84 days) prior to screening
Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti VEGF or anti-VEGF/anti-angiopoietin agent) in the SE, or surgery for nAMD in the SE, except dietary supplements or vitamins
History or evidence of any other clinically significant disorder, condition, disease or clinical laboratory abnormality that, in the opinion of the investigator or study medical monitor, if consulted, would pose a risk to participant safety or interfere with the study evaluation or results interpretation
Other protocol-specified exclusion criteria

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Santa Barbara?

Yes, this clinical trial (NCT07614776) has an active research site in Santa Barbara, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neovascular Age-related Macular Degeneration Treatment Options in Santa Barbara, CA

If you're searching for neovascular age-related macular degeneration treatment options in Santa Barbara, CA, this clinical trial (NCT07614776) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Santa Barbara research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neovascular age-related macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neovascular age-related macular degeneration clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Santa Barbara, CA

See all rheumatoid arthritis clinical trials recruiting in Santa Barbara — not just this study.

Browse Rheumatoid Arthritis Trials in Santa Barbara →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsErectile Dysfunction TrialsMacular Degeneration TrialsAll Conditions →

Ready to Join in Santa Barbara?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Santa Barbara, CA